NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free NCNA Stock Alerts $3.83 -0.17 (-4.25%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.75▼$4.0950-Day Range$3.78▼$10.5052-Week Range$3.40▼$23.75Volume12,017 shsAverage Volume58,676 shsMarket Capitalization$8.00 millionP/E RatioN/ADividend YieldN/APrice Target$125.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NuCana alerts: Email Address NuCana MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,163.7% Upside$125.00 Price TargetShort InterestHealthy0.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($12.06) to ($11.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuCana has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.35% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently decreased by 93.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for NuCana this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows7 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($12.06) to ($11.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About NuCana Stock (NASDAQ:NCNA)NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Read More NCNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCNA Stock News HeadlinesApril 18, 2024 | finance.yahoo.comNuCana plc (NCNA)April 16, 2024 | finance.yahoo.comNuCana Announces Completion of ADS Ratio ChangeApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 9, 2024 | globenewswire.comNuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyApril 5, 2024 | benzinga.comNuCana Stock (NASDAQ:NCNA), Quotes and News SummaryMarch 28, 2024 | msn.comWhy NuCana (NCNA) Shares Are Trading LowerMarch 27, 2024 | finanznachrichten.deNuCana plc: NuCana Announces Plan to Implement ADS Ratio ChangeMarch 27, 2024 | marketwatch.comNuCana American Depositary Shares Fall on News of Planned Ratio ChangeApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 27, 2024 | globenewswire.comNuCana Announces Plan to Implement ADS Ratio ChangeMarch 25, 2024 | markets.businessinsider.comNucana (NCNA) Receives a Hold from TD CowenMarch 20, 2024 | benzinga.comNuCana: Q4 Earnings InsightsMarch 20, 2024 | globenewswire.comNuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateMarch 14, 2024 | finance.yahoo.comNuCana (NASDAQ:NCNA) Will Have To Spend Its Cash WiselyMarch 13, 2024 | msn.comWhy NuCana Stock Is Up TodayMarch 13, 2024 | msn.comWhy Is Surgepays (SURG) Stock Down 27% Today?March 13, 2024 | investorplace.comWhy Is NuCana (NCNA) Stock Up 102% Today?February 27, 2024 | finanznachrichten.deNuCana plc: NuCana to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comNuCana to Present at TD Cowen’s 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comNuCana to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 26, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday TradingFebruary 23, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%February 6, 2024 | finanznachrichten.deNuCana plc: NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comNuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Wednesday TradingJanuary 3, 2024 | seekingalpha.comNuCana: Potential Turnaround In 2024 But RiskyDecember 29, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher FridaySee More Headlines Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today4/24/2024Next Earnings (Estimated)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$125.00 High Stock Price Target$150.00 Low Stock Price Target$100.00 Potential Upside/Downside+3,113.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($16.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.42% Return on Assets-72.84% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book0.44Miscellaneous Outstanding Shares2,090,000Free Float1,439,000Market Cap$8.13 million OptionableNot Optionable Beta0.92 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Hugh Stephen Griffith (Age 56)Founder, CEO & Executive Director Comp: $1.21MMr. Donald Munoz (Age 55)Chief Financial Officer Mr. David Harrison (Age 64)Head of Translational Medicine Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)M.D., Chief Medical Officer Ms. Theresa BruceSenior Vice President of Clinical OperationsMs. Elisabeth OelmannSenior Vice President of Medical & Clinical DevelopmentMartin QuinnCompany SecretaryMore ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMVirios TherapeuticsNASDAQ:VIRICyclerion TherapeuticsNASDAQ:CYCNHepion PharmaceuticalsNASDAQ:HEPAUniverse PharmaceuticalsNYSE:UPCView All Competitors NCNA Stock Analysis - Frequently Asked Questions Should I buy or sell NuCana stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NCNA shares. View NCNA analyst ratings or view top-rated stocks. What is NuCana's stock price target for 2024? 2 Wall Street analysts have issued twelve-month price objectives for NuCana's stock. Their NCNA share price targets range from $100.00 to $150.00. On average, they predict the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 3,163.7% from the stock's current price. View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts. How have NCNA shares performed in 2024? NuCana's stock was trading at $7.3950 at the beginning of the year. Since then, NCNA shares have decreased by 48.2% and is now trading at $3.83. View the best growth stocks for 2024 here. Are investors shorting NuCana? NuCana saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 164,900 shares, a decrease of 93.4% from the March 15th total of 2,480,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.4% of the shares of the stock are sold short. View NuCana's Short Interest. When is NuCana's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our NCNA earnings forecast. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($4.25) earnings per share for the quarter, missing the consensus estimate of ($3.25) by $1.00. When did NuCana's stock split? NuCana's stock reverse split on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH). When did NuCana IPO? NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NCNA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
